Amgen bone density drug shows positive results
Thousand Oaks-based pharmaceutical giant Amgen announced results Oct. 12 showing its bone density drug Prolia reduced the incidences of bone fractures in post-menopausal women with osteoporosis over 10 years. Prolia is designed to raise bone density in people with a history of osteoporosis. Amgen released the data during the annual conference of the American Society Read More →
Sientra CEO sends letter to surgeons saying implants are safe
Sientra CEO Hani Zeini sent another letter to plastic surgeons to reassure them that its products are safe. Sientra, a Goleta-based breast implant manufacturer, saw shares drop sharply over the past few months from a high of $23.75 on July 23. In recent weeks the stock fell from $20.58 on Sept. 23 to a close Read More →
Thousand Oaks company gives paraplegics mobility
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
U.K. crackdown sinks Sientra stock price
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
European regulators have good news for Amgen on cancer drugs
One of the world’s most expensive cancer drugs got conditional approval from European regulators on Sept. 25. Europeans granted Thousand Oaks-based Amgen conditional approval of its rare blood cancer drug Blincyto and gave a positive evaluation of Amgen’s multiple-myeloma drug Kyprolis. Blincyto is an immunotherapy that is designed to treat a rare form of leukemia Read More →
